597 related articles for article (PubMed ID: 32014107)
1. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies.
Pombo Antunes AR; Scheyltjens I; Duerinck J; Neyns B; Movahedi K; Van Ginderachter JA
Elife; 2020 Feb; 9():. PubMed ID: 32014107
[TBL] [Abstract][Full Text] [Related]
2. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
Desland FA; Hormigo A
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
[TBL] [Abstract][Full Text] [Related]
3. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
Kamran N; Chandran M; Lowenstein PR; Castro MG
Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.
Mineharu Y; Muhammad AK; Yagiz K; Candolfi M; Kroeger KM; Xiong W; Puntel M; Liu C; Levy E; Lugo C; Kocharian A; Allison JP; Curran MA; Lowenstein PR; Castro MG
Neurotherapeutics; 2012 Oct; 9(4):827-43. PubMed ID: 22996231
[TBL] [Abstract][Full Text] [Related]
5. Tumor-Specific T Cell Activation in Malignant Brain Tumors.
Mohme M; Neidert MC
Front Immunol; 2020; 11():205. PubMed ID: 32117316
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk Between Tumor-Associated Microglia/Macrophages and CD8-Positive T Cells Plays a Key Role in Glioblastoma.
Tu S; Lin X; Qiu J; Zhou J; Wang H; Hu S; Yao Y; Wang Y; Deng Y; Zhou Y; Shao A
Front Immunol; 2021; 12():650105. PubMed ID: 34394072
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.
Belmans J; Van Woensel M; Creyns B; Dejaegher J; Bullens DM; Van Gool SW
Sci Rep; 2017 Oct; 7(1):13902. PubMed ID: 29066810
[TBL] [Abstract][Full Text] [Related]
8. Immune infiltration of tumor microenvironment following immunotherapy for glioblastoma multiforme.
Sokratous G; Polyzoidis S; Ashkan K
Hum Vaccin Immunother; 2017 Nov; 13(11):2575-2582. PubMed ID: 28362548
[TBL] [Abstract][Full Text] [Related]
9. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
[TBL] [Abstract][Full Text] [Related]
10. Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme.
Zhang B; Shen R; Cheng S; Feng L
Cancer Med; 2019 Jun; 8(6):2897-2907. PubMed ID: 31038851
[TBL] [Abstract][Full Text] [Related]
11. Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma.
Fu W; Wang W; Li H; Jiao Y; Huo R; Yan Z; Wang J; Wang S; Wang J; Chen D; Cao Y; Zhao J
Front Immunol; 2020; 11():835. PubMed ID: 32457755
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma.
Lee AH; Sun L; Mochizuki AY; Reynoso JG; Orpilla J; Chow F; Kienzler JC; Everson RG; Nathanson DA; Bensinger SJ; Liau LM; Cloughesy T; Hugo W; Prins RM
Nat Commun; 2021 Nov; 12(1):6938. PubMed ID: 34836966
[TBL] [Abstract][Full Text] [Related]
13. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
[TBL] [Abstract][Full Text] [Related]
14. The network of immunosuppressive pathways in glioblastoma.
Mangani D; Weller M; Roth P
Biochem Pharmacol; 2017 Apr; 130():1-9. PubMed ID: 28017775
[TBL] [Abstract][Full Text] [Related]
15. Microglia-Centered Combinatorial Strategies Against Glioblastoma.
Martins TA; Schmassmann P; Shekarian T; Boulay JL; Ritz MF; Zanganeh S; Vom Berg J; Hutter G
Front Immunol; 2020; 11():571951. PubMed ID: 33117364
[TBL] [Abstract][Full Text] [Related]
16. The Role of Cytokines and Chemokines in Shaping the Immune Microenvironment of Glioblastoma: Implications for Immunotherapy.
Yeo ECF; Brown MP; Gargett T; Ebert LM
Cells; 2021 Mar; 10(3):. PubMed ID: 33803414
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for Glioblastoma: Current Progress and Challenges.
Yu MW; Quail DF
Front Immunol; 2021; 12():676301. PubMed ID: 34054867
[TBL] [Abstract][Full Text] [Related]
18. Macrophages/Microglia in the Glioblastoma Tumor Microenvironment.
Ma J; Chen CC; Li M
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071306
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development.
Majc B; Novak M; Kopitar-Jerala N; Jewett A; Breznik B
Cells; 2021 Jan; 10(2):. PubMed ID: 33572835
[TBL] [Abstract][Full Text] [Related]
20. Developing immunotherapeutic strategies to target brain tumors.
Lieberman NA; Moyes KW; Crane CA
Expert Rev Anticancer Ther; 2016 Jul; 16(7):775-88. PubMed ID: 27253692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
